Inoxgen

Nitric Oxide, the active ingredient in Inoxgen, is a vasodilator presented as a gas for inhalation use. It treats pulmonary hypertension and neonatal respiratory distress syndrome by relaxing pulmonary vascular smooth muscle and improving oxygen delivery. By increasing cyclic guanosine monophosphate (cGMP) levels, it leads to selective pulmonary vasodilation without systemic effects.

GNH USA supplies Inoxgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution.

Inoxgen is used as a pulmonary vasodilator to manage conditions affecting the pulmonary circulation, particularly where selective reduction of pulmonary vascular resistance is required and conventional systemic therapies are insufficient. - Pulmonary hypertension: lowers mean pulmonary arterial pressure, improves right‑ventricular function, and enhances exercise tolerance in adult patients. - Neonatal respiratory distress syndrome: increases pulmonary blood flow, improves ventilation‑perfusion matching, and raises arterial oxygen levels in affected newborns. - Post‑operative pulmonary hypertension: offers rapid pulmonary vasodilation to stabilize hemodynamics after cardiac or transplant surgery.

Inoxgen may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported during therapy. - Hypotension: transient drop in systemic blood pressure. - Flushing: facial or upper body flushing. - Cough: irritation of the airway causing cough. - Nausea: occasional nausea or upset stomach.

Serious or Rare Side Effects: - Methemoglobinemia: elevated methemoglobin levels reducing oxygen‑carrying capacity. - Rebound pulmonary hypertension: sudden increase in pulmonary pressure after abrupt discontinuation. - Severe hypotension: profound systemic blood pressure fall requiring intervention.

When prescribing Inoxgen, clinicians should consider several precautionary measures to ensure safe use. - Patient assessment: evaluate baseline pulmonary artery pressure and right‑ventricular function before initiation. - Monitoring: continuously monitor arterial oxygenation, methemoglobin levels, and systemic blood pressure during therapy. - Dose titration: adjust inhaled concentration gradually based on response and tolerability. - Contraindications: avoid use in patients with known hypersensitivity to nitric oxide or its delivery system. - Interaction caution: be vigilant when co‑administered with phosphodiesterase inhibitors or other vasodilators. - Store at ambient temperature: keep cylinders in original packaging, protect from moisture and direct sunlight.

Inoxgen can interact with other medications, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): combined use may cause severe hypotension. - Other inhaled vasodilators: additive pulmonary vasodilation can lead to excessive drop in pressure. - Methylene blue: reduces nitric oxide activity, diminishing therapeutic effect. - Systemic vasodilators (e.g., nitroprusside): risk of profound systemic hypotension.

Moderate Interactions (Monitor Closely): - Inhaled anesthetics (e.g., sevoflurane): may potentiate vasodilatory response. - Anticoagulants (e.g., heparin): increased bleeding risk due to vascular effects. - Nitric oxide donors (e.g., nitroglycerin): monitor for cumulative hypotensive effects. - Beta‑blockers: may blunt compensatory heart rate response, requiring monitoring.